Compare Crispr Therapeutics AG (CRSP) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Visa Inc — how do they compare? Crispr Therapeutics AG trades at $52.9 (market cap $4.88B), while Visa Inc trades at $382.08 (market cap $704.20B). The key difference: Visa Inc is far larger — about 144.3× Crispr Therapeutics AG's market cap, and Visa Inc pays a 0.71% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Visa Inc for 115 Days on average.
| CRSP | V | |
|---|---|---|
Market Cap | $4.88B | $704.20B |
Volume | 2,861,747 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $74.92 | $384.14 |
52-Week Low | $44.34 | $295.52 |
Typical Hold Time | 77 Days | 115 Days |
Enterprise Value | $3.30B | $714.78B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Visa (V) trades at $372.10, up 0.39% with strong bullish technical momentum. The company demonstrates robust fundamentals with 2025 revenue of $40B and net income margin of 50.78%. Recent earnings beats and a consensus price target of $422.24 reflect Wall Street optimism. Visa's expansion into AI-powered commerce through Intelligent Commerce Connect positions it for future growth while maintaining exceptional profitability metrics including 61.79% ROE.
Visa presents a compelling investment case with consistent earnings outperformance and dominant market position. Key opportunities include AI integration and stablecoin partnerships, while risks involve regulatory scrutiny and fintech competition. With 85% analyst buy ratings and 13% upside to consensus target, the stock offers growth potential despite premium valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
